Navigation Links
Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
Date:9/21/2007

ion for cisplatin treatment must be given.

Non-small cell lung cancer: The recommended dose of pemetrexed is 500 mg/m(squared) BSA, given by ten-minute infusion, on day 1 of each 21-day cycle.

Pre-medication: Supplement with 1000 micrograms intramuscular vitamin B12 and oral folic acid (350 to 1000 micrograms) to reduce toxicity (for full details see Summary of Product Characteristics [SPC]). To reduce the incidence and severity of skin reactions, a corticosteroid should be given the day prior to, on the day of, and the day after pemetrexed administration - this should be equivalent to 4mg of dexamethasone administered orally twice a day.

Monitoring: Monitor prior to each dose for complete blood cell count, including a differential white cell count and platelet count. Absolute neutrophil count should be > or = 1,500 cells/mm(cubed) and platelets > or = 100,000 cells/mm(cubed). Prior to each dose, collect blood chemistry tests to evaluate renal and hepatic function. Dose adjustments to pemetrexed and/or cisplatin at the start of a subsequent cycle should be based on nadir haematological counts or maximum non-haematological toxicity. If necessary, delay or withhold treatment in the presence of haematological toxicity, neurotoxicity, and/or impaired hepatic/renal function. (For full information on dose modification see SPC.)

Children and adolescents: Not recommended for use in patients under 18 years of age.

Renal impairment: Patients with creatinine clearance > or = 45 ml/min require no dose adjustment other than those recommended for all patients. Use in patients with creatinine clearance below 45 ml/min is not recommended. See also Warnings and Special Precautions.

Hepatic impairment: Patients with hepatic impairment, such as bilirubin >1.5-times the upper limit of normal and/or transaminase >3.0-times the upper limit of normal (hepatic metastases absent) or >5.0-times the upper limit of normal (hepatic metastases present), have n
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer Treatment
2. Making Science Personal: Lilly Oncology to Unveil 76 Studies at ASCO 2007
3. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
4. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
5. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Malvern initiates European user group meetings for chemical imaging
9. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
10. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
11. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...Nov. 6 Derma Sciences,...advanced wound care products, announced plans to r...t on Monday, November 16, 2009. The Company will h... results at 11:00 am EST. Interested parties shoul... (international), with passcode 81416481 to access...
(Date:11/6/2009)... Nov. 6 Philips Respironics applau...and Prevention (CDC) to raise awareness about an i...fficiency. The CDC,s release of the first-ever gov...s in sleeplessness is a milestone in quantifying t...-time educator, industry leader and sleep therapy ...
(Date:11/6/2009)...PRNewswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq:...ort financial results for the second quarter ended...30, 2010 on Wednesday, November 18, 2009 at 5:00 P... to discuss those results on Thursday, November 19...cond Quarter Results Conference Call Instructions ...
Breaking Medicine Technology:Derma Sciences Announces Date of Its Third Quarter 2009 Earnings Release and Conference Call 2Statement by Don Spence, CEO, Philips Home Healthcare Solutions, Endorsing CDC Educational Initiatives to Raise Awareness of Sleep Deprivation 2Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results 2Ulcerative colitis treatment reduces need for surgery by almost half 58614 1Ulcerative colitis treatment reduces need for surgery by almost half 58614 2Platelet rich plasma 3A Does it work 3F 58610 1Platelet rich plasma 3A Does it work 3F 58610 2Platelet rich plasma 3A Does it work 3F 58610 3Entomological Society of America names 2009 award winners 10202 1Entomological Society of America names 2009 award winners 10202 2
...16 DURECT Corporation (Nasdaq: DRRX ) announced...b clinical trial conducted by Endo Pharmaceuticals...ay patch under development for the treatment of ch...candidate was reviewed with the U.S. Food and Drug...hase II meeting with the FDA on February 19, 2009....
...nnocoll, Inc., a privately-held biopharmaceutical ...dosed in the first of two ongoing U.S. phase 3 cli...ary, Innocoll Technologies Ltd, to investigate Col...tion of surgical site infections. , , The trial i...es across the U.S. and has enrolled 1,500 diabetic...
Other Medicine Technology:DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program 2DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program 3DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program 4DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program 5Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients 2Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients 3
(Date:11/8/2009)...swire-USNewswire/ -- Pharmaceutical Research and M...ent Ken Johnson released the following statement r..."We are disappointed, but not surprised by today,s...orking Americans as well as nearly half of the mem...d against the bill. ,, "While well intentioned,...
(Date:11/8/2009)...ho Sides With Working Families vs. Insurance Compa...Newswire/ -- On the heels of an historic late nigh... balanced health care reform bill, the Pennsylvani...U.S. representatives voted on HR 3962, the Afforda...ation, which passed Saturday evening by a vote of ...
(Date:11/7/2009)...Newswire-USNewswire/ -- Speaker Nancy Pelosi spok..., the Affordable Health Care for America Act. The... Below are the Speaker,s remarks. ,, "Madam S...nt for our nation and for American families. For ...ical philosophy -- as far back as Teddy Roosevelt ...
(Date:11/7/2009)...re/ -- Calling this a "defining moment" for the Am...t J. James Rohack, M.D., today addressed medical s...edical specialty societies at the opening of the A...th system reform will top the agenda. ,, (Logo:...ALOGO ) ,, "Over the next 72 hours, this AMA ...
(Date:11/7/2009)...swire-USNewswire/ -- The U.S. bishops November 7 u...te for the Stupak-Ellsworth Amendment to the healt...aptur-Dahlkemper-Lipinski-Smith Amendment will kee... and conscience protections in the Affordable Heal..., The letter was signed by Cardinal Justin Riga...
Breaking Medicine News(10 mins):Health News:PhRMA Statement on House Passage of Health Care Reform Bill 2Health News:PhRMA Statement on House Passage of Health Care Reform Bill 3Health News:Robert Brady (D-PA-1), Chaka Fattah (D-PA-2), Kathy Dahlkemper (D-PA-3), Joe Sestak (D-PA-7), Patrick Murphy (D-PA-8), Christopher Carney (D-PA-10), John Murtha (D-PA-12), Paul Kanjorski (D-PA-11), Allyson Schwartz (D-PA-13), Mike Doyle (D-PA-14) Ge 2Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 2Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 3Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 4Health News:AMA President Kicks Off AMA Meeting Focused on Health Reform 2Health News:Bishops Urge Passage of Stupak-Ellsworth Anti-Abortion Amendment for Health Reform Bill 2
...itive Proxy Materials, BEDFORD, Mass., Sept. 12 ... of state-of-the-art diagnostic and,digital imagin...nnounced,that its registration statement, includin...nce mailing,definitive proxy materials in connecti...
...A (Sept. 12, 2007) Most of us have never heard of...ive parents from conceiving. , Immune infertilit...includes better-known diseases like Multiple Scler...ery at the University of Virginia Health System ma...
... disease showed effect after brief exposure to die...thDay News) -- Here,s a good reason not to take ...e heart disease who were exposed, even briefly, to...ks and arrhythmias. , The levels of pollution simu...
... Ahead on Reconciling Separate Bills, Despite the,...inistration Roadblocks, WASHINGTON, Sept. 12 U.S...to work out differences between their,separate ver...w many additional children would be covered in eac...
...ernor Calls the Quilt a ,Beautiful Symbol, NEW YO...ribed by her daughter, Jean Bolds, as "a homemaker...Henderson-Bolds took care of her,family --- hangin...u at the front door and you couldn,t,wait to eat!"...
...courage Muslims to use discipline of Ramadan fast ...HINGTON, Sept. 12 A prominent national,Islamic ci...s representing,American Muslim physicians today en... lunar calendar during which,Muslims abstain from ...
Other Medicine News:Health News:Hologic Sets Special Meeting of Stockholders to Vote on Proposed Merger with Cytyc Corporation 2Health News:Hologic Sets Special Meeting of Stockholders to Vote on Proposed Merger with Cytyc Corporation 3Health News:Hologic Sets Special Meeting of Stockholders to Vote on Proposed Merger with Cytyc Corporation 4Health News:UVA researchers find important clue to immune infertility 2Health News:Jogging in Traffic Cuts Blood Flow to Heart 2Health News:Jogging in Traffic Cuts Blood Flow to Heart 3Health News:Congress Poised to Add Millions of Uninsured Children to Successful, Bipartisan Health Plan 2Health News:Congress Poised to Add Millions of Uninsured Children to Successful, Bipartisan Health Plan 3Health News:Alzheimer's Foundation of America to Display Quilt to Remember in Los Angeles 2Health News:Alzheimer's Foundation of America to Display Quilt to Remember in Los Angeles 3Health News:Muslim Groups Kick Off Ramadan With Anti-Smoking Initiative 2Health News:Muslim Groups Kick Off Ramadan With Anti-Smoking Initiative 3
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
Medicine Products: